Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5TYMG)

• Drug Name: LY86057 Drug Info
• Synonyms: LY-86057; LY 86057

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 13878025
  TTD Drug ID: DM5TYMG

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 2B receptor (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[4]
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[5]
Minaprine	DM0EP7M	Depression	6A70-6A7Z	Approved	[6]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[7]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[8]
PRX-08066	DMR7H2V	Pulmonary arterial hypertension	BB01.0	Phase 2	[9]
Pyrimidine derivative 29	DMVOYJ8	N. A.	N. A.	Patented	[10]
Pyrimidine derivative 26	DM90WKN	N. A.	N. A.	Patented	[10]
Pyrimidine derivative 23	DM5MLQU	N. A.	N. A.	Patented	[10]
Pyrimidine derivative 25	DM51MFS	N. A.	N. A.	Patented	[10]

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[4]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[11]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[12]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[13]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[14]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[15]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[16]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[17]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[18]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Antagonist	[2]
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Antagonist	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 184).
• [2] Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86.
• [3] Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26.
• [4] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [5] Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
• [6] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [7] New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
• [8] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
• [9] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [10] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
• [11] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [12] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [13] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [14] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [15] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [17] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [18] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [19] Clinical pipeline report, company report or official report of Lundbeck.